A carregar...
P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience
Bevacizumab is an anti-VEGF antibody used in the treatment of recurrent glioblastoma (GBM). Despite the available literature, few is known about the best schedule to administer this angiogenesis inhibitor: i) early, at the first recurrence, or ii) later, after a second line of chemotherapy. In this...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464262/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.297 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|